| __timestamp | Amicus Therapeutics, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 79696000 |
| Thursday, January 1, 2015 | 76943000 | 93236000 |
| Friday, January 1, 2016 | 104793000 | 150842000 |
| Sunday, January 1, 2017 | 149310000 | 150643000 |
| Monday, January 1, 2018 | 270902000 | 150252000 |
| Tuesday, January 1, 2019 | 286378000 | 140804000 |
| Wednesday, January 1, 2020 | 308443000 | 34236000 |
| Friday, January 1, 2021 | 272049000 | 35672000 |
| Saturday, January 1, 2022 | 276677000 | 66607000 |
| Sunday, January 1, 2023 | 152381000 | 76363000 |
| Monday, January 1, 2024 | 79048000 |
Data in motion
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Amicus Therapeutics, Inc. and Halozyme Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Amicus Therapeutics increased its R&D spending by over 220%, peaking in 2020. This surge underscores their aggressive pursuit of groundbreaking therapies. In contrast, Halozyme's R&D expenses fluctuated, with a notable decline of nearly 75% from 2016 to 2020, reflecting a strategic pivot or potential resource reallocation. As of 2023, Amicus's R&D expenditure remains nearly double that of Halozyme, highlighting their sustained focus on innovation. This analysis provides a window into the strategic priorities of these biotech firms, offering insights into their future growth trajectories.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Strategic Focus on R&D Spending
GSK plc or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
R&D Insights: How Summit Therapeutics Inc. and Halozyme Therapeutics, Inc. Allocate Funds
Research and Development Investment: Halozyme Therapeutics, Inc. vs PTC Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Pharming Group N.V. vs Amicus Therapeutics, Inc.
Research and Development Expenses Breakdown: ADMA Biologics, Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: ACADIA Pharmaceuticals Inc. vs Amicus Therapeutics, Inc.
R&D Spending Showdown: Amicus Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.
Research and Development Investment: Amicus Therapeutics, Inc. vs Viridian Therapeutics, Inc.